Effectiveness and cost-effectiveness of treatment with additional enrollment to a homeopathic integrated care contract in Germany

Table 3 Adjusted means (95% CI) of diagnosis-specific primary effectiveness measures, diagnosis-specific group differences and minimal clinical important differences, 6 months of follow-up

	HOM group		CON group
Diagnosis	N	Adj. mean (95% CI)	N	Adj. mean (95% CI)	Group Δ*	p-value^†	Minimal clinical important difference^‡ reached?
Migraine/headache Days with headache (last 4 weeks)	400	3.7 (2.2–5.2)	266	4.6 (2.9–6.3)	−0.9	0.042	No
Allergic rhinitis RQLQ(S) score	283	1.6 (1–2.2)	167	1.8 (1.2–2.5)	−0.2	0.209	No
Asthma AQLQ(S) score	111	5.8 (5.4–6.3)	66	5.4 (4.9–5.9)	0.4	0.014	No
Atopic dermatitis DLQI score	206	6.8 (4.5–9.1)	97	8.2 (5.5–10.9)	− 1.4	0.086	No
Depression BDI-II score	423	14.1 (11.9–16.3)	334	19.7 (17.2–22.2)	−5,6	< 0.001	Yes

*HOM group minus CON group, ^† adjusted for age, sex, education, residential state, complementary medicine affiliation, per protocol initial anamnesis, baseline value of diagnosis specific scores, ^‡Minimal clinical important differences refer to the diagnoses specific primary effectiveness outcomes (see Table 1), judgement for migraine/headache depends on expert opinion

ISSN: 1472-6963